

Contents

Part I Introduction – Epigenetics 1

- 1 **Epigenetics: Moving Forward** 3
Lucia Altucci
- 1.1 Why This Enormously Increased Interest? 4
- 1.2 Looking Forward to New Avenues of Epigenetics 5
- Acknowledgments 7
- References 7

Part II General Aspects/Methodologies 11

- 2 **Structural Biology of Epigenetic Targets: Exploiting Complexity** 13
Martin Marek, Tajith B. Shaik, and Christophe Romier
- 2.1 Introduction 13
- 2.2 DNA Methylases: The DNMT3A–DNMT3L–H3 and DNMT1–USP7 Complexes 14
- 2.3 Histone Arginine Methyltransferases: The PRMT5–MEP50 Complex 16
- 2.4 Histone Lysine Methyltransferases: The MLL3–RBBP5–ASH2L and the PRC2 Complexes 17
- 2.5 Histone Lysine Ubiquitinylases: The PRC1 Complex 21
- 2.6 Histone Lysine Deubiquitinylases: The SAGA Deubiquitination Module 22
- 2.7 Histone Acetyltransferases: The MSL1 and NUA4 Complexes 24
- 2.8 Histone Deacetylases: HDAC1–MTA1 and HDAC3–SMRT Complexes and HDAC6 26
- 2.9 Histone Variants and Histone Chaperones: A Complex and Modular Interplay 28

- 2.10 ATP-Dependent Remodelers: CHD1, ISWI, SNF2, and the SNF2-Nucleosome Complex 31
- 2.11 Epigenetic Readers: Histone Crotonylation Readers and the 53BP1-Nucleosome (H2AK15Ub–H4K20me2) Complex 35
- 2.12 Conclusions 37
- Acknowledgments 38
- References 38

3 Computer-based Lead Identification for Epigenetic Targets 45

Chiara Luise, Tino Heimburg, Berin Karaman, Dina Robaa, and Wolfgang Sippl

- 3.1 Introduction 45
- 3.2 Computer-based Methods in Drug Discovery 46
 - 3.2.1 Pharmacophore-based Methods 46
 - 3.2.2 QSAR 47
 - 3.2.3 Docking 47
 - 3.2.4 Virtual Screening 48
 - 3.2.5 Binding Free Energy Calculation 49
- 3.3 Histone Deacetylases 49
 - 3.3.1 Zinc-Dependent HDACs 49
 - 3.3.2 Sirtuins 54
- 3.4 Histone Methyltransferases 58
- 3.5 Histone Demethylases 61
 - 3.5.1 LSD1 (KDM1A) 62
 - 3.5.2 Jumonji Histone Demethylases 64
- 3.6 Summary 66
- Acknowledgments 66
- References 67

4 Mass Spectrometry and Chemical Biology in Epigenetics Drug Discovery 79

Christian Feller, David Weigt, and Carsten Hopf

- 4.1 Introduction: Mass Spectrometry Technology Used in Epigenetic Drug Discovery 79
 - 4.1.1 Mass Spectrometry Workflows for the Analysis of Proteins 80
 - 4.1.2 Mass Spectrometry Imaging 83
- 4.2 Target Identification and Selectivity Profiling: Chemoproteomics 85
 - 4.2.1 Histone Deacetylase and Acetyltransferase Chemoproteomics 87
 - 4.2.2 Bromodomain Chemoproteomics 88
 - 4.2.3 Demethylase Chemoproteomics 88
 - 4.2.4 Methyltransferase Chemoproteomics 89
- 4.3 Characterization of Epigenetic Drug Target Complexes and Reader Complexes Contributing to Drug's Mode of Action 89
 - 4.3.1 Immunoaffinity Purification of Native Protein Complexes 89
 - 4.3.2 Immunoaffinity Purification with Antibodies Against Epitope Tags 90

4.3.3	Affinity Enrichment Using Histone Tail Peptides as Bait	91
4.4	Elucidation of a Drug's Mode of Action: Analysis of Histone Posttranslational Modifications by MS-Based Proteomics	91
4.4.1	Histone Modification MS Workflows	92
4.4.2	Application of Histone MS Workflows to Characterize Epigenetic Drugs	95
4.5	Challenges and New Trends	97
4.5.1	Challenges and Trends in MS Analysis of Histone PTMs	97
4.5.2	High-Throughput Mass Spectrometry-Based Compound Profiling in Epigenetic Drug Discovery	98
4.5.3	Mass Spectrometry Imaging of Drug Action	98
	Acknowledgments	99
	References	99

5 Peptide Microarrays for Epigenetic Targets 107

Alexandra Schutkowski, Diana Kalbas, Ulf Reimer, and Mike Schutkowski

5.1	Introduction	107
5.2	Applications of Peptide Microarrays for Epigenetic Targets	110
5.2.1	Profiling of Substrate Specificities of Histone Code Writers	110
5.2.2	Profiling of Substrate Specificities of Histone Code Erasers	114
5.2.3	Profiling of Binding Specificities of PTM-specific Antibodies and Histone Code Readers	117
5.2.3.1	Profiling of Specificities of PTM-specific Antibodies	118
5.2.3.2	Profiling of Binding Specificities of Histone Code Readers	119
5.2.4	Peptide Microarray-based Identification of Upstream Kinases and Phosphorylation Sites for Epigenetic Targets	121
5.3	Conclusion and Outlook	124
	Acknowledgment	124
	References	124

6 Chemical Probes 133

Amy Donner, Heather King, Paul E. Brennan, Moses Moustakim, and William J. Zuercher

6.1	Chemical Probes Are Privileged Reagents for Biological Research	133
6.1.1	Best Practices for the Generation and Selection of Chemical Probes	134
6.1.2	Best Practices for Application of Chemical Probes	136
6.1.3	Cellular Target Engagement	137
6.1.3.1	Fluorescence Recovery After Photobleaching (FRAP)	138
6.1.3.2	Affinity Bead-Based Proteomics	138
6.1.3.3	Cellular Thermal Shift Assay (CETSA)	139
6.1.3.4	Bioluminescence Resonance Energy Transfer	139
6.2	Epigenetic Chemical Probes	141
6.2.1	Histone Acetylation and Bromodomain Chemical Probes	141
6.2.1.1	CBP/p300 Bromodomain Chemical Probes	144
6.2.1.2	Future Applications of Bromodomain Chemical Probes	147

6.3	Summary	147
	References	148

Part III Epigenetic Target Classes 153

7	Inhibitors of the Zinc-Dependent Histone Deacetylases	155
	<i>Helle M. E. Kristensen, Andreas S. Madsen, and Christian A. Olsen</i>	
7.1	Introduction: Histone Deacetylases	155
7.2	Histone Deacetylase Inhibitors	158
7.2.1	Types of Inhibitors	158
7.2.2	HDAC Inhibitors in Clinical Use and Development	160
7.3	Targeting of HDAC Subclasses	169
7.3.1	Class I Inhibitors	169
7.3.1.1	HDAC1–3 Inhibitors	170
7.3.1.2	HDAC Inhibitors Targeting HDAC8	173
7.3.2	Class IIa Inhibitors	174
7.3.3	Class IIb	176
7.4	Perspectives	177
	References	179
8	Sirtuins as Drug Targets	185
	<i>Clemens Zwergel, Dante Rotili, Sergio Valente, and Antonello Mai</i>	
8.1	Introduction	185
8.2	Biological Functions of Sirtuins in Physiology and Pathology	185
8.3	SIRT Modulators	188
8.3.1	SIRT Inhibitors	188
8.3.1.1	Small Molecules	188
8.3.1.2	Peptides and Pseudopeptides	191
8.3.2	SIRT Activators	191
8.4	Summary and Conclusions	192
	References	193
9	Selective Small-Molecule Inhibitors of Protein Methyltransferases	201
	<i>H. Ümit Kaniskan and Jian Jin</i>	
9.1	Introduction	201
9.2	Protein Methylation	201
9.3	Lysine Methyltransferases (PKMTs)	202
9.4	Inhibitors of PKMTs	202
9.4.1	Inhibitors of H3K9 Methyltransferases	202
9.4.2	Inhibitors of H3K27 Methyltransferases	204
9.4.3	Inhibitors of H3K4 and H3K36 Methyltransferases	206
9.4.4	Inhibitors of H4K20 Methyltransferases	208
9.4.5	Inhibitors of H3K79 Methyltransferases	210
9.5	Protein Arginine Methyltransferases (PRMTs)	211

9.5.1	Inhibitors of PRMT1	211
9.5.2	Inhibitors of PRMT3	212
9.5.3	Inhibitors of CARM1	213
9.5.4	Inhibitors of PRMT5	214
9.5.5	Inhibitors of PRMT6	214
9.6	Concluding Remarks	215
	References	215
10	LSD (Lysine-Specific Demethylase): A Decade-Long Trip from Discovery to Clinical Trials	221
	<i>Adam Lee, M. Teresa Borrello, and A. Ganesan</i>	
10.1	Introduction	221
10.2	LSDs: Discovery and Mechanistic Features	223
10.3	LSD Substrates	225
10.4	LSD Function and Dysfunction	229
10.5	LSD Inhibitors	232
10.5.1	Irreversible Small Molecule LSD Inhibitors from MAO Inhibitors	233
10.5.2	Reversible Small Molecule LSD Inhibitors	241
10.5.3	Synthetic Macromolecular LSD Inhibitors	248
10.6	Summary	251
	References	253
11	JmjC-domain-Containing Histone Demethylases	263
	<i>Christoffer Højrup, Oliver D. Coleman, John-Paul Bukowski, Rasmus P. Clausen, and Akane Kawamura</i>	
11.1	Introduction	263
11.1.1	The LSD and JmjC Histone Lysine Demethylases	263
11.1.2	Histone Lysine Methylation and the JmjC-KDMs	265
11.1.3	The JmjC-KDMs in Development and Disease	266
11.2	KDM Inhibitor Development Targeting the JmjC Domain	272
11.2.1	2-Oxoglutarate Cofactor Mimicking Inhibitors	273
11.2.1.1	Emulation of the Chelating α -Keto Acid Moiety in 2OG	273
11.2.1.2	Bioisosteres of the Conserved 2OG C5-Carboxylic Acid-Binding Motif	273
11.2.2	Histone Substrate-Competitive Inhibitors	275
11.2.2.1	Small-Molecule Inhibitors	276
11.2.2.2	Peptide Inhibitors	276
11.2.3	Allosteric Inhibitors	276
11.2.4	Inhibitors Targeting KDM Subfamilies	277
11.2.4.1	KDM4 Subfamily-Targeted Inhibitors	277
11.2.4.2	KDM4/5 Subfamily-Targeted Inhibitors	279
11.2.4.3	KDM5 Subfamily-Targeted Inhibitors	280
11.2.4.4	KDM6 Subfamily-Targeted Inhibitors	281
11.2.4.5	KDM2/7- and KDM3-Targeted Inhibitors	282
11.2.4.6	Generic JmjC-KDM Inhibitors	282
11.2.5	Selectivity and Potency of JmjC-KDM Inhibition in Cells	283

11.3	KDM Inhibitors Targeting the Reader Domains	284
11.3.1	Plant Homeodomain Fingers (PHD Fingers)	284
11.3.2	Tudor Domains	286
11.4	Conclusions and Future Perspectives	286
	Acknowledgments	287
	References	287
12	Histone Acetyltransferases: Targets and Inhibitors	297
	<i>Gianluca Sbardella</i>	
12.1	Introduction	297
12.2	Acetyltransferase Enzymes and Families	298
12.3	The GNAT Superfamily	299
12.3.1	KAT2A/GCN5 and KAT2B/PCAF	301
12.3.2	KAT1/Hat1	303
12.3.3	GCN5L1	304
12.4	KAT3A/CBP and KAT3B/p300 Family	304
12.5	MYST Family	306
12.5.1	KAT5/Tip60	306
12.5.2	KAT6A/MOZ, KAT6B/MORE, and KAT7/HBO1	307
12.5.3	KAT8/MOF	307
12.5.4	SAS2 and SAS3	308
12.5.5	ESA1	308
12.5.6	Other KATs	308
12.6	KATs in Diseases	309
12.7	KAT Modulators	312
12.7.1	Bisubstrate Inhibitors	313
12.7.2	Natural Products and Synthetic Analogues and Derivatives	315
12.7.3	Synthetic Compounds	321
12.7.4	Compounds Targeting Protein–Protein Interaction Domains	328
12.8	Conclusion	333
	References	334
13	Bromodomains: Promising Targets for Drug Discovery	347
	<i>Mehrosh Pervaiz, Pankaj Mishra, and Stefan Günther</i>	
13.1	Introduction	347
13.2	The Human Bromodomain Family	348
13.2.1	Structural Features of the Human BRD Family	348
13.2.1.1	The K_{ac} Binding Site	348
13.2.1.2	Druggability of the Human BRD Family	350
13.2.2	Functions of Bromodomain-containing Proteins	352
13.3	Bromodomains and Diseases	353
13.3.1	The BET Family	354
13.3.2	Non-BET Proteins	356
13.4	Methods for the Identification of Bromodomain Inhibitors	357
13.4.1	High-throughput Screening (HTS)	357
13.4.2	Fragment-based Lead Discovery	359
13.4.3	Structure-based Drug Design	359

13.4.4	Virtual Screening	362
13.4.4.1	Structure-based Virtual Screening	362
13.4.4.2	Ligand-based Virtual Screening	362
13.4.4.3	Pharmacophore Modeling	363
13.4.4.4	Substructure and Similarity Search	363
13.5	Current Bromodomain Inhibitors	364
13.6	Multi-target Inhibitors	365
13.6.1	Dual Kinase–Bromodomain Inhibitors	365
13.6.2	Dual BET/HDAC Inhibitors	369
13.7	Proteolysis Targeting Chimeras (PROTACs)	369
13.8	Conclusions	371
	Acknowledgments	372
	References	372
14	Lysine Reader Proteins	383
	<i>Johannes Bacher, Dina Robaa, Chiara Luise, Wolfgang Sippl, and Manfred Jung</i>	
14.1	Introduction	383
14.2	The Royal Family of Epigenetic Reader Proteins	385
14.2.1	The MBT Domain	385
14.2.2	The PWWP Domain	390
14.2.3	The Tudor Domain	392
14.2.4	The Chromodomain	395
14.3	The PHD Finger Family of Epigenetic Reader Proteins	400
14.4	The WD40 Repeat Domain Family	402
14.5	Conclusion and Outlook	409
	Acknowledgment	409
	References	409
15	DNA-modifying Enzymes	421
	<i>Martin Roatsch, Dina Robaa, Michael Lübbert, Wolfgang Sippl, and Manfred Jung</i>	
15.1	Introduction	421
15.2	DNA Methylation	422
15.3	Further Modifications of Cytosine Bases	424
15.4	DNA Methyltransferases: Substrates and Structural Aspects	426
15.5	Mechanism of Enzymatic DNA Methylation	430
15.6	Physiological Role of DNA Methylation	431
15.7	DNA Methylation in Disease	432
15.8	DNMT Inhibitors	433
15.8.1	Nucleoside-mimicking DNMT Inhibitors	433
15.8.2	Non-nucleosidic DNMT Inhibitors	436
15.9	Therapeutic Applications of DNMT Inhibitors	441
15.10	Conclusion	442
	Acknowledgment	443
	References	443

16	Parasite Epigenetic Targets	457
	<i>Raymond J. Pierce and Jamal Khalife</i>	
16.1	Introduction: The Global Problem of Parasitic Diseases and the Need for New Drugs	457
16.2	Parasite Epigenetic Mechanisms	458
16.2.1	DNA Methylation	459
16.2.2	Histone Posttranslational Modifications	460
16.2.3	Histone-modifying Enzymes in Parasites	462
16.2.4	HMEs Validated as Therapeutic Targets	462
16.2.5	Structure-based Approaches for Defining Therapeutic Targets	464
16.3	Development of Epi-drugs for Parasitic Diseases	465
16.3.1	Repurposing of Existing Epi-drugs	466
16.3.2	Candidates from Phenotypic or High-throughput Screens	467
16.3.3	Structure-based Development of Selective Inhibitors	467
16.4	Conclusions	468
	Acknowledgments	469
	References	469
	Index	477